FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

For research purposes only. Full disclaimer →

Peptide Library

Melanotan II

MT-2 / MT-II

Beauty & Skincare

Melanotan II is a synthetic cyclic heptapeptide analog of alpha-melanocyte stimulating hormone (alpha-MSH) that acts as a non-selective agonist at melanocortin receptors MC1R through MC5R. Developed at the University of Arizona in the 1990s, it was originally investigated for sunless tanning (photoprotection) but its non-selective receptor profile produces multiple effects including skin darkening, sexual arousal, appetite suppression, and nausea. It remains one of the most widely used research peptides globally despite never receiving regulatory approval and carrying a significant side effect profile.

Mechanism of Action

Non-selective melanocortin receptor agonist. Activates MC1R (tanning), MC3R/MC4R (sexual arousal and appetite suppression), and MC5R (exocrine gland function). Produces tanning, increases sexual arousal, and suppresses appetite through simultaneous multi-receptor activation.

Research Protocols

For research purposes only. Not medical advice.

Research protocols use 0.25-0.5mg daily via subcutaneous injection as a loading phase for 7-14 days. Maintenance: 0.5mg 1-2 times weekly. Start with low doses (0.25mg) to assess nausea tolerance. Some UV exposure accelerates tanning.

Research Notes

Clinical Research Status

Melanotan II was investigated in early clinical trials at the University of Arizona for photoprotection and erectile dysfunction but was never advanced to Phase 3 or regulatory approval. Clinuvel Pharmaceuticals developed a related selective MC1R agonist (afamelanotide/Scenesse) that received FDA approval for erythropoietic protoporphyria. Melanotan II itself remains unregulated in most jurisdictions and is widely available through gray market suppliers.

Key Published Findings

Clinical studies confirmed dose-dependent melanogenesis (skin darkening) without UV exposure, though UV co-exposure significantly enhances and accelerates tanning response. Research documented spontaneous penile erections in male subjects during early dose-finding studies, leading to the development of PT-141. Studies show significant appetite suppression through MC4R activation, with measurable reductions in food intake at standard tanning doses.

Safety Profile

The non-selective melanocortin agonism produces a broad side effect profile including nausea (very common at initiation), facial flushing, fatigue, and involuntary stretching/yawning. Serious concerns include darkening of existing moles and nevi, which complicates dermatological skin cancer surveillance. Case reports document new nevus formation and changes in existing moles that required biopsy. The TGA (Australia) and FDA have issued warnings against its use due to safety concerns and lack of regulatory oversight.

Drug Interactions & Contraindications

Absolutely contraindicated in individuals with personal or family history of melanoma or dysplastic nevus syndrome due to potential promotion of melanocyte proliferation. Should not be used with other melanocortin agonists (PT-141, afamelanotide). Caution with antihypertensive medications due to potential for transient blood pressure changes. UV exposure combined with Melanotan II may increase melanoma risk compared to either alone.

Comparison to Related Compounds

PT-141 (bremelanotide) was derived from Melanotan II specifically to isolate the MC4R-mediated sexual function effects while minimizing MC1R tanning activity. Afamelanotide (Scenesse) is a linear alpha-MSH analog designed for selective MC1R activation for photoprotection without significant sexual or appetite effects. Melanotan I (afamelanotide) is selective for MC1R while Melanotan II activates all five melanocortin receptor subtypes.

Community Observations

Typically initiated with a loading protocol of 250-500mcg daily subcutaneously for 2-4 weeks, then maintained at 500mcg once or twice weekly with UV exposure. Nausea is nearly universal during the first 3-5 doses and commonly managed with antihistamines or by dosing before sleep. Users report significant skin darkening within 1-2 weeks and should be counseled about mandatory dermatological monitoring of moles and any new skin lesions.

Half Life

~30-60 minutes

Reconstitution

Bacteriostatic water (BAC)

Storage

Lyophilized

Refrigerate 2-8C up to 24 months. Protect from light.

Reconstituted

Refrigerate 2-8C. Use within 30 days.

US Legal Status

Research chemical (not FDA-approved)

Also Known As

MT-2MT-II

Frequently Asked Questions

What is Melanotan II?

Melanotan II is a synthetic cyclic heptapeptide analog of alpha-melanocyte stimulating hormone (alpha-MSH) that acts as a non-selective agonist at melanocortin receptors MC1R through MC5R. Developed at the University of Arizona in the 1990s, it was originally investigated for sunless tanning (photoprotection) but its non-selective receptor profile produces multiple effects including skin darkening, sexual arousal, appetite suppression, and nausea. It remains one of the most widely used research peptides globally despite never receiving regulatory approval and carrying a significant side effect profile.

How does Melanotan II work?

Non-selective melanocortin receptor agonist. Activates MC1R (tanning), MC3R/MC4R (sexual arousal and appetite suppression), and MC5R (exocrine gland function). Produces tanning, increases sexual arousal, and suppresses appetite through simultaneous multi-receptor activation.

What is the US regulatory status of Melanotan II?

Research chemical (not FDA-approved)

What is the half-life of Melanotan II?

~30-60 minutes

What else is Melanotan II called?

MT-2, MT-II

Peptide Contacts provides research-based summaries for informational purposes only. We do not host, distribute, or endorse vendor documentation. All certificates of analysis, GMP certificates, and vendor communications must be requested and verified directly by the buyer. Nothing on this platform constitutes legal, medical, or professional advice. Users are solely responsible for verifying vendor credentials and ensuring compliance with all applicable local, state, and federal laws before purchasing any research chemicals. Use of this platform constitutes acceptance of full personal responsibility.

Read full disclaimer